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Background: It has been proposed that the AT2 receptor exerts beneficial effects in post-myocardial infarction (MI) remodeling. In this regard, a 
recent publication indicated that pharmacological AT2 receptor stimulation may significantly reduce infarct size and ameliorate cardiac function 
after MI. Hence, in this study we aimed to further explore the effect of AT2 receptor deficiency (KO) as well as pharmacological AT2 receptor 
stimulation on post-MI morbidity and mortality using an established mouse model of MI.
Methods: Myocardial infarction was induced in KO and wildtype (WT) mice by permanent ligation of the left coronary artery. In a subgroup of 
WT mice the AT2 receptor agonist CGP42112A was administered by osmotic minipumps for 7 days post-MI. Subsequently, we studied infarction-
associated mortality (within the first 7 days after infarction). Moreover, vascular remodeling (neovascularization) and inflammatory infiltrates were 
analysed 7 days post-MI using computer-aided histomorphometrical methods.  In addition, cardiac function was assessed by echocardiography and 
systemic blood pressure was measured invasively using a tip-pressure catheter.
Results: Surprisingly, infarction-associated mortality was higher in mice treated with CGP42112A (62%; n=26) as compared to mice treated 
with vehicle (40%; n=15; P<0.05). In addition, we observed a trend towards increased survival of KO mice as compared to WT mice. Moreover, 
echocardiographical assessment revealed a non-significant trend towards reduced systolic function in mice treated with CGP42112A, whereas 
cardiac function of KO mice did not differ from that observed in WT mice. In addition, CGP42112A treatment suppressed monocyte recruitment to 
the infarcted region. In contrast, neither CGP42112A treatment nor AT2 receptor deficiency were associated with changes in vascular remodeling or 
systemic blood pressure.
Conclusion: In conclusion, our data indicate that CGP42112A-induced AT2 receptor stimulation may increase post-MI mortality in a blood 
pressure-independent fashion by mechanisms apparently not involving post-MI vascular remodeling.
